Life-Sciences Group NV, Europe’s leading biotech company in the storage, expansion, research and development of therapeutic applications for human tissues and cells, has been nominated for the Deloitte Technology Fast 500 2006 award.

Life-Sciences Group NV is proud to be the only biotech company among the 500 nominees for the 2006 award. CEO M. Waeterschoot: ”The Deloitte Fast500 nomination for Life-Sciences Group NV is a true acknowledgement of the tremendous efforts made by all our employees to develop our company into the European leader in storage of human tissues and stem cells and to conduct further research and development in these fields. We consider this nomination as a cornerstone in positioning our research driven company as an active investor in the field of stem cell technology.”


To be nominated for the Technology Fast 500 award, candidates must demonstrate:

About Deloitte Technology Fast500

• exceptional growth rate over the last five years in comparison to other peer competitors
• significant investments in research and development
• capabilities to develop and operate own technology
• a track record of at least five years

Ultimately the winning company will be awarded for its fast-growing achievements during a special event taking place on 28 September in Amsterdam.

About Life-Sciences Group NV

Life-Sciences Group NV was founded in March 2000. Core business of Life-Sciences Group is currently the processing of cord blood and the preservation of cord blood stem cells, scientifically based upon cryo-technology (-196°C). The company’s brand name Cryo-Save Labs is the leading family stem cell bank in Europe with over 40.000 samples. Driven by its corporate social responsibility, Cryo-Save Labs has engaged itself into partnerships pro deo with the Red Cross and the Belgian Foundation for Children with Cancer.

The particular storage methods were developed through intense research and development and are internationally patented. Processing and preservation of cord blood stem cells takes place in modern laboratories nearby Brussels, Belgium. Additional laboratories in Europe are also operational in Bonn and Mannheim (Germany). In September 2006 a new state-of-the-art laboratory will be officially opened in Dubai (United Arab Emirates). Due to the constant growth and geographical expansion, investments in other laboratories are scheduled for 2007 in Istanbul (Turkey), Moscow (Russia) and Mumbai (India). Life- Sciences Group has established collaborations on different promising projects with leading universities in Europe in stem cell research.

Currently Life-Sciences Group has activities in 28 countries and three continents (EMEA, Europe, Middle East, Africa), offers employment to more than 100 highly qualified people and has a portfolio of more than 55.000 customers.

For further information about Life-Sciences Group NV, its activities and services, please visit us at www.life-sciences.com or contact us through e-mail info@life-sciences.com or

Marc Waeterschoot, CEO +32 495 501 949
Peter Tulkens, Communications +32 477 198 067